RECCE PHARMACEUTICALS LTD — Director's Dealing 2019

Dec 18, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd (Company) ABN 73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Hamilton Bray Graham
Date of last notice	7 March 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	19 December 2019

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	Direct Interest: 1. 1,868,601 ordinary shares 2. 389,712 Class B Performance Shares 3. 389,712 Class C Performance Shares 4. 389,712 Class D Performance Shares Indirect Interest: Mr. James Graham 1. 1,781,250 ordinary shares 2. 356,250 Class B Performance Shares 3. 356,250 Class C Performance Shares 4. 356,250 Class D Performance Shares Bulleen Pty Ltd 1. 650,000 ordinary shares
Class	Fully Paid Ordinary Shares
Number acquired	192,307 ordinary shares
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.26 per ordinary share
No. of securities held after change	Direct Interest: 1. 2,060,908 ordinary shares 2. 389,712 Class B Performance Shares 3. 389,712 Class C Performance Shares 4. 389,712 Class D Performance Shares Indirect Interest: Mr. James Graham 1. 1,781,250 ordinary shares 2. 356,250 Class B Performance Shares 3. 356,250 Class C Performance Shares 4. 356,250 Class D Performance Shares Bulleen Pty Ltd 1. 650,000 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	192,307 fully paid ordinary shares were issued to Mr Graham for his participation in the placement as announced on 10 October 2019, where Mr Graham subscribed for $50,000 worth of shares in the Company. The Company received shareholder approval for the share issue at the Annual General Meeting held on 25 November 2019.

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3